{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bennstein SB"],"funding":["Deutsche Forschungsgemeinschaft"],"pagination":["797432"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8739490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["Innate lymphoid cells (ILCs) and in particular ILC3s have been described to be vital for mucosal barrier functions and homeostasis within the gastrointestinal (GI) tract. Importantly, IL-22-secreting ILC3 have been implicated in the control of inflammatory bowel disease (IBD) and were shown to reduce the incidence of graft-versus-host disease (GvHD) as well as the risk of transplant rejection. Unfortunately, IL-22-secreting ILC3 are primarily located in mucosal tissues and are not found within the circulation, making access to them in humans challenging. On this account, there is a growing desire for clinically applicable protocols for <i>in vitro</i> generation of effector ILC3. Here, we present an approach for faithful generation of functionally competent human ILC3s from cord blood-deri"],"journal":["Frontiers in immunology"],"pubmed_title":["Efficient <i>In Vitro</i> Generation of IL-22-Secreting ILC3 From CD34<sup>+</sup> Hematopoietic Progenitors in a Human Mesenchymal Stem Cell Niche."],"pmcid":["PMC8739490"],"funding_grant_id":["SPP1937-UH91/8-1 (MU), FOR2033, TP B3 (RAJO)"],"pubmed_authors":["Weinhold S","Bennstein SB","Oostendorp RAJ","Degistirici O","Raba K","Meisel R","Walter L","Kogler G","Uhrberg M"],"additional_accession":[]},"is_claimable":false,"name":"Efficient <i>In Vitro</i> Generation of IL-22-Secreting ILC3 From CD34<sup>+</sup> Hematopoietic Progenitors in a Human Mesenchymal Stem Cell Niche.","description":"Innate lymphoid cells (ILCs) and in particular ILC3s have been described to be vital for mucosal barrier functions and homeostasis within the gastrointestinal (GI) tract. Importantly, IL-22-secreting ILC3 have been implicated in the control of inflammatory bowel disease (IBD) and were shown to reduce the incidence of graft-versus-host disease (GvHD) as well as the risk of transplant rejection. Unfortunately, IL-22-secreting ILC3 are primarily located in mucosal tissues and are not found within the circulation, making access to them in humans challenging. On this account, there is a growing desire for clinically applicable protocols for <i>in vitro</i> generation of effector ILC3. Here, we present an approach for faithful generation of functionally competent human ILC3s from cord blood-deri","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2026-05-09T05:54:37.951Z","creation":"2022-02-11T15:09:52.292Z"},"accession":"S-EPMC8739490","cross_references":{"pubmed":["35003122"],"doi":["10.3389/fimmu.2021.797432"]}}